Expert Protein Quantitation by MRM-MS
PEPTIQUANT™ PROTEIN QUANTITATION
MRM Proteomics offers sample analysis using our high quality PeptiQuant™ Plus technology to quantify up to 300 proteins from a single sample.
Our PeptiQuant™ Plus assays employ a rigorous MRM-MS quantitation strategy that uses paired heavy/light peptide standards – a minimum of two synthetic peptides for every protein quantified.
The unlabeled “light” peptide is used to create the calibration curve, whereas the “heavy”’ SIS peptide is spiked into every sample at a fixed concentration. Using separate standards for calibration and normalization ensures robust and precise measurements, even at low concentrations.
- Highly multiplexed panels for accurate quantitation of 100s of proteins from a single sample
- High purity paired heavy/light peptide standards for precise quantitation of every targeted protein
- Quality MRM-MS technology you can trust: all assays are highly reproducible, rigorously tested for intereferences, and characterized according to Tier II CPTAC guidelines
- Panels include med-low abundance proteins associated with cancer, CVD, and other diseases
- Compatible with a variety of sample types
- Minimal sample volume (25-100 uL)
- Suited to complex matrices analysis (plasma, CSF, urine etc.)
- Extremely high specificity (not possible with antibody-based
- Discrimination of protein isoforms
- Depletion or enrichment not required
- No antibodies required
Cardiovascular disease>60 proteins
|Low-volume samples||Extreme coverage (2D)||Extra sensitivity||Advanced validation|
Our highly-multiplexed panels are tailored for a wide variety of applications.
By LeBlanc, A., Michaud, S.A., Percy, A.J., Hardie, D.B., Yang, J., Sinclair, N.J., Proudfoot, J.I., Pistawka, A., Smith, D.S. and Borchers, C.H.
Oct 01 2016
By Percy AJ, Hardie DB, Jardim A, Yang J, Elliott MH, Zhang S, Mohammed Y, Borchers CH
Nov 01 2016
By Percy AJ, Michaud SA, Jardim A, Sinclair NJ, Zhang S, Mohammed Y, Palmer AL, Hardie DB, Yang J, LeBlanc AM, Borchers CH.
By Hirtz, Christophe, Jérôme Vialaret, Nora Nowak, Audrey Gabelle, Dominique Deville de Périère, and Sylvain Lehmann
Jun 30 2014
By Percy AJ, Yang J, Chambers AG, Simon R, Hardie DB, Borchers CH..
Dec 01 2013
By Percy AJ, Byrns S, Chambers AG,
Targeted mass spectrometry assays were characterized at the UVic-Genome BC Proteomics Centre according to the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) assay characterization guidelines (https://assays.cancer.gov/guidance-document). Initial characterization data (produced in a human plasma matrix), can be viewed on the CPTAC Assay Portal (https://assays.cancer.gov). Note: Specific kits may use a different type of matrix from the human plasma that was used to generate the CPTAC fit-for-purpose characterization data, and thus assay performance from this kit may vary from that reported on the CPTAC Assay Portal. The CPTAC assay characterization guidance documents were developed as a direct outcome of a workshop (Carr et al., Mol Cell Proteomics 2014; PMID 24443746) sponsored by the CPTAC program.